{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:59:33Z","timestamp":1792821573726,"version":"4.5.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The efficacy of chemotherapy in locally advanced, recurrent, and metastatic salivary gland carcinomas (LA-R\/M SGCs) is still undefined. We aimed to compare the efficacy of two chemotherapy regimens in LA-R\/M SGC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This prospective study compared paclitaxel (Taxol) plus carboplatin (TC) versus cyclophosphamide, doxorubicin, plus cisplatin (CAP) regimen in terms of overall response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS), and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Between October 2011 and April 2019, 48 patients with LA-R\/M SGCs were recruited. The ORRs of first-line TC and CAP regimens were 54.2% and 36.3%, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.57). The ORRs in recurrent and\n                      <jats:italic toggle=\"yes\">de novo<\/jats:italic>\n                      metastatic patients were 50.0% and 37.5% for TC and CAP, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.26). The median PFS of TC and CAP arms were 10.2 and 11.9 months, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.91). In the subanalysis, patients with adenoid cystic carcinoma (ACC) had longer PFS in the TC arm (14.5 vs. 8.2 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03), irrespective of the tumor grade (low grade: 16.3 vs. 8.9 months, high grade: 11.7 vs. 4.5 months;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03). The median OS rates were 45.5 and 19.5 months for TC and CAP groups, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.71).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>For patients with LA-R\/M SGC, there was no significant difference between first-line TC and CAP in terms of ORR, PFS, and OS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijc.ijc_1226_20","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T03:30:51Z","timestamp":1696044651000},"page":"418-426","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["A comparison of two chemotherapy regimens in advanced, recurrent, or metastatic salivary gland carcinoma"],"prefix":"10.4103","volume":"60","author":[{"given":"Ahmad","family":"Ameri","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainaz","family":"Sourati","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnaz","family":"Behzadi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Lesan","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Taghizadeh-Hesary","sequence":"additional","affiliation":[{"name":"ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran"},{"name":"Radiation Oncology Department, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.otpol.2012.09.003","article-title":"Ocena epidemiologiczna nowotwor\u00f3w gruczo\u0142\u00f3w \u015blinowych u pacjent\u00f3w leczonych w Klinice Otolaryngologii we Wroc\u0142awiu w latach 2001\u20132010","volume":"67","author":"Kubacka","year":"2013","journal-title":"Otolaryngol Pol"},{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3109\/00016489.2016.1170876","article-title":"Combination chemotherapy of carboplatin and paclitaxel for advanced\/metastatic salivary gland carcinoma patients:Differences in responses by different pathological diagnoses","volume":"136","author":"Nakano","year":"2016","journal-title":"Acta Otolaryngol"},{"key":"R3-20240828","first-page":"1","article-title":"Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer","volume":"7","author":"Debaere","year":"2011","journal-title":"B-ENT"},{"key":"R4-20240828","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11864-011-0174-0","article-title":"Recurrent salivary gland cancer","volume":"13","author":"Gillespie","year":"2012","journal-title":"Curr Treat Options Oncol"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/j.seminoncol.2008.03.009","article-title":"Salivary gland malignancies:The role for chemotherapy and molecular targeted agents","volume":"35","author":"Surakanti","year":"2008","journal-title":"Semin Oncol"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3109\/00016489.2016.1170876","article-title":"Combination chemotherapy of carboplatin and paclitaxel for advanced\/metastatic salivary gland carcinoma patients:Differences in responses by different pathological diagnoses","volume":"136","author":"Nakano","year":"2016","journal-title":"Acta Otolaryngol"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/oxfordjournals.annonc.a010684","article-title":"Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients","volume":"7","author":"Licitra","year":"1996","journal-title":"Ann Oncol"},{"key":"R9-20240828","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R10-20240828","first-page":"3781","article-title":"Paclitaxel and carboplatin for recurrent salivary gland malignancies","volume":"20","author":"Airoldi","year":"2000","journal-title":"Anticancer Res"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/hed.10034","article-title":"Response to paclitaxel and carboplatin in metastatic salivary gland cancer:A case report","volume":"24","author":"Ruzich","year":"2002","journal-title":"Head Neck"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cncr.24745","article-title":"A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer:A trial of the NCIC clinical trials group","volume":"116","author":"Laurie","year":"2010","journal-title":"Cancer"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"843","DOI":"10.21873\/invivo.11549","article-title":"Carboplatin and docetaxel in patients with salivary gland carcinoma:A retrospective study","volume":"33","author":"Okada","year":"2019","journal-title":"In Vivo"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hed.20327","article-title":"Phase II trial of taxol in salivary gland malignancies (E1394):A trial of the Eastern Cooperative oncology group","volume":"28","author":"Gilbert","year":"2006","journal-title":"Head Neck"},{"key":"R15-20240828","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1097-0142(20010201)91:3<541::AID-CNCR1032>3.0.CO;2-Y","article-title":"Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies","volume":"91","author":"Airoldi","year":"2001","journal-title":"Cancer"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3389\/fonc.2019.00701","article-title":"First line androgen deprivation therapy vs. chemotherapy for patients with androgen receptor positive recurrent or metastatic salivary gland carcinoma-A retrospective study","volume":"9","author":"Viscuse","year":"2019","journal-title":"Front Oncol"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/0002-9610(74)90265-7","article-title":"Adenoid cystic carcinoma of salivary origin:A clinicopathologic study of 242 cases","volume":"128","author":"Spiro","year":"1974","journal-title":"Am J Surg"},{"key":"R18-20240828","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1470-2045(10)70245-X","article-title":"Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands:A systematic review","volume":"12","author":"Laurie","year":"2011","journal-title":"Lancet Oncol"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_1226_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:16:34Z","timestamp":1787166994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_1226_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_1226_20","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"2020-10-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}